Physician profile
Rafath Ullah
NPI 1326350034
$5,962.41
in general payments reported to CMS, 2019-2025
14 companies · $59.41 in 2025
The $59.41 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,253 · 2023: $4,442 · 2024: $208 · 2025: $59.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,539 · Food and Beverage: $999 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,539.46 |
| Food and Beverage | $999.00 |
| Education | $170.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $2,462.60 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Medtronic, INC. | $1,344.98 | 2022-2023 | Corevalve Evolut R |
| Boston Scientific Corporation | $1,266.79 | 2022-2023 | Versacross Access Solution, Opticross |
| Novartis Pharmaceuticals Corporation | $195.99 | 2023-2024 | |
| Abbott Laboratories | $149.13 | 2022-2025 | Cardiomems |
| Asahi Intecc USA, INC. | $131.04 | 2022 | |
| Shockwave Medical, INC | $111.29 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Actelion Pharmaceuticals US, INC. | $99.99 | 2023 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $68.99 | 2023 | Brilinta |
| Veryan Medical Incorporated | $48.33 | 2022 | |
| Angiodynamics, INC. | $48.25 | 2022 | |
| Cleerly, INC. | $31.86 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Surmodics, INC. | $3.17 | 2025 | Sublime 014 Rx Pta Balloon Dilatation Catheter, Pounce Thrombectomy, Sublime Microcatheter, 018, 200cm, Straight |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafath Ullah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.